According to Bausch Health and Glenmark, Health Canada has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in people aged 6 and older. Bausch Health acquired the Canadian rights to Ryaltris in March 2021. Ryaltris has been approved in Australia since December 2019, in Europe since April 2021 and in the US since January 2022.
Bausch Health Senior VP, Europe and Canada, Cees Heiman commented, “This Health Canada approval will allow Bausch Health to soon make Ryaltris available to Canadians, providing an innovative therapy option for seasonal allergic rhinitis. This is part of our ongoing commitment to being a trusted partner in the healthcare of Canadians.”
Glenmark Pharmaceuticals Global Formulations Business CEO Brendan O’Grady said, “We are very pleased that Bausch Health, Canada will soon be able to bring the benefits of the novel drug Ryaltris to the patients in Canada seeking a new treatment for seasonal allergic rhinitis. Ryaltris is a result of our consistent efforts to offer high-quality medicines that benefit patients around the world, and now coming to Canada, adding to our global respiratory leadership.”
Read the Bausch Health and Glenmark Pharmaceuticals press release.
